Pegaptanib for neovascular age-related macular degeneration.

By E. Gragoudas, A. Adamis, E. Cunningham, M. Feinsod, D. Guyer. New England Journal of Medicine, 2004

2,264 citations recorded by the source corpus.

Subfields: Epidemiology, Ophthalmology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/ad6e957889b99f719ddd12095b49a061c3559f5c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. A. Adamis
2. N. Ferrara
3. D. Hanahan

In Ophthalmology

1. M. Zarbin
2. Don H. Anderson
3. N. Ferrara
4. L. V. Johnson
5. G. Hageman
6. K. Eng
7. P. Kertes
8. N. Bhagat

In Radiology, Nuclear Medicine and Imaging

1. N. Ferrara
2. L. V. Johnson
3. K. Eng
4. P. Kertes
5. N. Bhagat
6. R. Grigorian
7. A. Adamis
8. A. Tutela

Citations in the corpus

• Aptamers as therapeutics (2010, methodology): “Pegaptanib 69 was approved for therapeutic use by the uS Food and Drug Administration in December 2004 and is currently marketed by Pfizer and Eyetech as macugen.”
• Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors (2008, background): “PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3554 The involvement of VEGF in AMD has led to the Food and Drug Administration approval of two intraocular anti-VEGF drugs, pegaptanib sodium (Macugen, OSI/Eyetech Pharmaceuticals, NY) [12], an aptamer which was reported to inhibit”
• Diabetic macular edema: pathogenesis and treatment. (2009, background): “Blockage of VEGF has shown to reduce vascular permeability.(125,129,282) VEGF inhibition has been achieved via PKC inhibitors as well as high affinity binding of either aptamers (e.”
• Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action. (2006, background): “In addition to cancer therapy, the FDA recently approved Macugen [13] (pegaptanib), an aptamer of VEGF, for the treatment of macular degeneration.”
• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “Pegaptanib, the first anti-VEGFA aptamer for an ocular disease, was approved in 2004 for neovascular AMD, based on the VISION trials, which found that it was associated with reduced vision loss compared with sham injection 194 .”
• Treating metastatic cancer with nanotechnology (2011, background): “Pegaptanib, an anti-angiogenic aptamer-based agent, is being used clinically for the treatment of macular degeneratio”
• Scientific and medical aspects of ozone therapy. State of the art. (2006, background): “The neovascular, exudative (or wet form) must be first treated with photodynamic therapy (46) or radiation (47) or with other experimental approaches based on blocking the activity of extracellular vascular endothelial growth factor (48).”
• Angiogenesis as a therapeutic target (2005, background): “In December 2004, the FDA approved pegaptinib, an aptamer that blocks the 165 amino-acid isoform of VEGF-A, for the treatment of the wet (neovascular) form of age-related macular degeneration (AMD”
• Interfering with disease: a progress report on siRNA-based therapeutics (2007, methodology): “The only approved oligonucleotide-based drugs are used in the eye -Vitravene® to treat CMV retinitis 103 and Macugen® for AMD 104 .”